ANGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hold is the right call. ANGO has improving fundamentals and positive analyst support, but it does not yet offer a clean, high-confidence long-term entry for a beginner investor today. The stock is near resistance, options positioning is bearish, and there is no fresh catalyst. For an impatient investor wanting to act now, this is not the best buy.
ANGO is trading at 11.27, right near its pivot level of 10.973 and just below R1 at 11.309, which suggests the stock is testing resistance rather than breaking out decisively. MACD histogram is positive and expanding, which supports short-term upward momentum. RSI_6 at 66.06 is near overbought but still in a neutral-to-bullish zone, so the move is extended but not overheated. Moving averages are converging, indicating the trend is improving but not yet fully established. Overall, the technical picture is mildly bullish, but not strong enough for an aggressive long-term buy at this exact level.
["Freedom Broker initiated coverage with a Buy rating and a $16 target, pointing to an improved growth profile from higher-growth medical technology platforms.", "Canaccord kept a Buy rating and maintained a $16 target after a strong FQ3, citing a revenue beat and raised guidance.", "Latest quarter showed revenue growth of 8.91% YoY, indicating the business is still expanding.", "Net loss and EPS loss improved significantly year over year, showing operational progress.", "MACD is positive and expanding, supporting improving momentum.", "No recent insider selling, no significant hedge fund pressure, and no recent congress trading activity."]
["No news in the recent week, so there is no near-term catalyst driving the stock higher.", "Gross margin declined to 49.49%, showing some pressure on profitability quality.", "The options market shows a strong bearish tilt with a 2.06 put-call open interest ratio.", "RSI is near the upper end of the range, limiting immediate upside attractiveness for a fresh entry.", "Moving averages are only converging, not strongly trending upward yet.", "Hedge funds and insiders are neutral, which does not provide a strong supportive ownership signal."]
In the latest reported quarter, Q3 2026, AngioDynamics delivered revenue of $78.42 million, up 8.91% year over year, which is a solid growth sign. Net income improved meaningfully, though it remained negative at -$8.08 million, and EPS improved to -$0.19 from a deeper loss year over year. This shows the company is moving in the right direction operationally, but it is still not profitable. Gross margin slipped to 49.49%, down 1.73% YoY, which tempers the growth story slightly. Overall, the latest quarter was better, but still not strong enough to justify a high-conviction long-term buy on fundamentals alone.
Analyst sentiment has improved recently. On 2026-04-06, Freedom Broker initiated coverage with a Buy rating and a $16 target, highlighting a better growth profile. On the same date, Canaccord lowered its target to $16 from $18 but kept a Buy rating, citing a good FQ3 with a revenue beat and raised guidance. The Wall Street pros view is cautiously positive: they like the strategic pivot and improving growth, but some remain concerned about EBITDA optics and the still-limited profitability profile. That means the consensus tone is bullish, but not strongly conviction-driven.
